House Fails to Override Presidential Veto of L-HHS Funding Bill
On November 13, President Bush vetoed the Labor-Health and Human Services-Education (L-HHS) spending package that he received from Congress. Bush had vowed to veto any domestic spending bill that exceeded his proposed budget, and the L-HHS bill did so by nearly $10 billion....
|
Legislation Introduced to Halt DXA Payment Cuts; Study Shows Costs to Perform Tests Higher than 2007 Reimbursement
The Endocrine Society strongly endorses H.R. 4206, the Medicare Fracture Prevention and Osteoporosis Testing Act, introduced on November 15, 2007, by Representative Shelley Berkley (D-NV). If enacted, this legislation would restore physician payments for dual energy x-ray absorptiometry (DXA) and vertebral fracture assessment (VFA) services to their 2006 levels....
|
Society Pushes AMA to Reduce Minority Health Disparities in Clinical Research
Last week, during the semi-annual meeting of the American Medical Association (AMA) House of Delegates (HOD) in Honolulu, HI, The Endocrine Society’s delegation advocated strongly for a Society-sponsored resolution to increase minority participation in clinical trials....
|
Grant Opportunities
The Endocrine Society attempts to keep its members informed of opportunities for research grants from different sources. Four such opportunities are outlined below....
|
New ICD-9 Diagnosis Codes to Affect Endocrine Practices
The Centers for Disease Control and Prevention’s (CDC) National Center for Health Statistics (NCHS) recently released its periodic list of new International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9) diagnosis codes. A number of these new codes specifically affect endocrinology, and practitioners should immediately alter their billing practices to reflect these changes....
|
New Requirements for Registering Clinical Trials; HHS Provides Information to Researchers
The Protocol Registration System (PRS) of ClinicalTrials.gov has information online regarding new registration and reporting requirements. The information is intended to help those who conduct clinical trials to navigate the requirements set forth in the Food and Drug Administration Amendments Act of 2007, which was signed into law by the president earlier this year (U.S. Public Law 110-85)....
|
The Endocrine Society’s Executive Director Honored by American Medical Association
The American Medical Association (AMA) honored Scott Hunt, executive director and chief executive officer of The Endocrine Society, with the 2007 Medical Executive Meritorious Achievement Award. The award is given to a medical association executive who has demonstrated exceptional service and contributions to the goals and ideals of the medical profession....
|
Revised Warning Label on Avandia Reflects Potential Heart-Related Risk, Inconclusive Data
The U.S. Food and Drug Administration (FDA) and GlaxoSmithKline (GSK) have agreed that the black box warning on Avandia (rosiglitazone) should be revised to include results from a meta-analysis of 42 clinical studies. The revised warning will indicate that the meta-analysis revealed an increased risk of myocardial ischemic events in patients taking Avandia when compared to placebo....
|
